

# SRI JAYADEVA'S NON-PROFIT ENDEAVOURS



Dr. C. N. Manjunath, Director

**S**ri Jayadeva Institute of Cardiovascular Sciences and Research is a government-run autonomous institute with 1150

beds exclusively for cardiac care and is one of the largest single centres for heart care in South East Asia. This is purely a non-profit organization with state-of-art cardiac care facilities, providing quality cardiac care at an affordable cost to all sections of society and free of cost to the deserving poor. It has effectively implemented “Treatment First – Payment Next” concept wherein any cardiac patient requiring emergency admission is attended to without insisting for any advance payment. The institute has recorded 500 per cent growth in last 10 years.

Sri Jayadeva Institute of Cardiovascular Sciences and Research has got the state-of-art equipments in the form of seven cathlabs, seven operation theatres, non-invasive laboratories and 24 hours ICU facilities. It is

NABH accredited and has got the biggest post graduate tteaching programme in the country. Presently on an average 1500-1700 patients visit this hospital every day and annually 40,000 in-patients are treated. About 3000 open heart surgeries, 30000 cathlab procedures including coronary angiograms, angioplasties, valvuloplasties, pacemaker, device closures and other procedures are done in this hospital. Annually nearly 1,500 open heart operations and angioplasties are done free of cost for poor patients. Seventy five per cent of the patients who come to hospital are well below the poverty line.

The hospital has qualified, skilled, full-time faculty which includes 90 cardiologists, 35 cardiothoracic surgeons and 20 cardiac anesthetists with supporting ancillary staff and department. Sri Jayadeva has state-of-art branches in Mysuru, Kalaburagi and ESI-MH Rajajinagar in addition to the main center.

breast cancer isn't as frightening as it might have been earlier. With the growing realization that each patient is unique, and each patient's tumour is as unique due to inherent genetic differences a clear move away from the one-size-fits-all approach is evident especially in the treatment of cancer patients. Today, not all women diagnosed with early-stage breast cancer need to undergo chemotherapy. OncoStem's CanAssist-Breast is designed to classify patients depending on the risk of cancer recurrence. By analysing the patient's tumour biology, CanAssist-Breast identifies 'low-risk' patients who will have minimal benefit of adding chemotherapy to their treatment



and 'high-risk' patients who will benefit the most by adding it." Cancer is a heterogeneous disease, meaning differences exist not only between cancer cells from various patients, but also between cancer cells within a single patient. Dr. Niti Raizada, Sr. Consultant Medical Oncologist & Hemato-Oncologist, Vikram Hospital, Bengaluru, says, "Precision therapy matches the most effective treatment to the individual cancer patient based on the molecular profiling of the specific cancer, and can be divided into two categories that include precision chemo-targeted therapy and precise therapeutic procedures. Precision chemo-targeted therapy is the use of the correct drugs prescribed